Relmada Therapeutics, Inc.
(NASDAQ : RLMD)

( )
RLMD After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.43%178.760.7%$1159.00m
LLYEli Lilly & Co. -0.18%370.421.1%$1137.20m
MRKMerck & Co., Inc. -0.26%109.830.7%$1033.23m
PFEPfizer Inc. 2.02%51.140.9%$991.81m
ABBVAbbVie, Inc. 0.25%161.581.9%$866.05m
BMYBristol-Myers Squibb Co. 0.74%80.871.1%$771.68m
AZNAstraZeneca Plc 0.54%68.341.0%$358.11m
HZNPHorizon Therapeutics Plc 0.59%100.885.4%$309.21m
IDXXIDEXX Laboratories, Inc. 3.12%439.173.9%$229.98m
CTLTCatalent, Inc. 4.21%52.241.9%$213.67m
GSKGSK Plc 1.29%35.040.3%$189.77m
NVSNovartis AG 0.28%89.810.2%$186.33m
NVONovo Nordisk A/S 1.22%126.130.1%$172.82m
ALNYAlnylam Pharmaceuticals, Inc. -0.15%220.258.0%$161.43m
RGENRepligen Corp. 5.22%188.176.7%$134.32m

Company Profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.